

Updated: 10/2020 DMMA Approved: 10/2020

Request for Prior Authorization for Epidiolex (cannabidiol) Website Form – www.highmarkhealthoptions.com Submit request via: Fax - 1-855-476-4158

All requests for Epidiolex (cannabidiol) require a prior authorization and will be screened for medical necessity and appropriateness using the criteria listed below.

Epidiolex (cannabidiol) Prior Authorization Criteria:

For all requests for Epidiolex (cannabidiol) all of the following criteria must be met:

- Treatment is prescribed by, or in consultation with, a neurologist
- Medication must be used as adjunctive therapy with another antiepileptic drug
- Member must be 1 years of age or older
- The requested dose and frequency is in accordance with FDA-approved labeling, nationally recognized compendia, and/or evidence-based practice guidelines

Coverage may be provided with a <u>diagnosis</u> of Lennox-Gastaut syndrome and the following criteria is met:

- The member experienced at least 8 seizures in the last month while on stable antiepileptic drug therapy
- Must provide documentation showing the member has tried and failed (which will be verified via pharmacy claims if available) or had an intolerance or contraindication to all of the following:
 - o Valproate
 - o Lamotrigine
 - o At least **one** of the following:
 - Rufinamide
 - Topiramate
 - Felbamate
 - Clobazam (requires prior authorization)
- **Initial Duration of Approval**: 6 months
- Reauthorization criteria:
 - Must provide documentation showing treatment with Epidiolex has provided improvement in the member's condition.
- **Reauthorization duration of approval**: 12 months

Coverage may be provided with a <u>diagnosis</u> of Dravet syndrome and the following criteria is met:

- The member experienced at least 4 convulsive seizures in the last month while on stable antiepileptic drug therapy.
- Must provide documentation showing the member has tried and failed (which will be verified via pharmacy claims if available) or had an intolerance or contraindication to all of the following:
 - o Valproate



Updated: 10/2020 DMMA Approved: 10/2020

- Clobazam (requires prior authorization)
- o Topiramate
- o At least **one** of the following:
 - Clonazepam
 - Levetiracetam
 - Zonisamide
- Initial Duration of Approval: 6 months
- Reauthorization criteria:
 - Must provide documentation showing treatment with Epidiolex has provided improvement in the member's condition.
- Reauthorization duration of approval: 12 months

Coverage may be provided with a <u>diagnosis</u> of Tuberous Sclerosis Complex and the following criteria is met:

- Member must have experienced the following over the past 4 weeks while on stable antiepileptic drug therapy:
 - o At least 8 total seizures
 - o At least 1 focal seizure occurring in at least 3 of the 4 weeks.
- Member must have tried and failed a ketogenic diet or provide patient-specific rationale for inappropriateness
- If member has a glioneuronal hamartoma or tuber, must have failed surgical management or provide patient-specific rationale for inappropriateness
- Must provide documentation showing the member has tried and failed (which will be verified via pharmacy claims if available) or had an intolerance or contraindication to at least one other antiepileptic drug and everolimus (requires prior authorization).
- **Initial Duration of Approval**: 6 months
- Reauthorization criteria:
 - Must provide documentation showing treatment with Epidiolex has provided improvement in the member's condition.
- **Reauthorization duration of approval**: 12 months

Coverage may be provided for any non-FDA labeled indication if it is determined that the use is a medically accepted indication supported by nationally recognized pharmacy compendia or peer-reviewed medical literature for treatment of the diagnosis(es) for which it is prescribed. These requests will be reviewed on a case by case basis to determine medical necessity.



Updated: 10/2020 DMMA Approved: 10/2020

CANNABIDIOL (EPIDIOLEX) (PAGE 1 of 2) PRIOR AUTHORIZATION FORM

Please complete and fax all requested information below including any progress notes, laboratory test results, or chart documentation as applicable to Highmark Health Options Pharmacy Services. **FAX:** (855) 476-4158

If needed, you may call to speak to a Pharmacy Services Representative.

If needed, you may call to speak to a Pharmacy Services Representative.							
PHONE : (844) 325-6251 Monday through Friday 8:30am to 5:00pm							
	PROVIDER I	NFORMA					
Requesting Provider:			NPI:				
	Provider Specialty:			Office Contact:			
Office Address: Office Phone:							
Office Fax:							
	MEMBER IN		ΓΙΟΝ				
Member Name:		DOB:					
Health Options ID:		Member		pounds orkg			
	REQUESTED DRI			N .			
Medication: Streng							
Frequency: Dura							
· ·	s the member currently receiving requested medication? Yes No Date Medication Initiated:						
	chronic or long-term condit	ion for wh	ich the med	dication may be necessary for the life of			
the patient? Yes No							
		nformation	n				
This medication will be billed: at a pharmacy OR							
	medically (if medically ple						
Place of Service: Hospital		mber's ho		er			
	Place of Servi	ice Inform					
Name:			NPI:				
Address:			Phone:				
	MEDICAL HISTORY (C						
Does the member have a diagnosis of Lennox-Gastaut Syndrome, Dravet Syndrome or Tuberous Sclerosis Complex? Yes No							
Number of seizures per month							
Is the medication going to be used as adjunctive therapy to other antiepileptic drugs? Yes No							
If member has a diagnosis of Tuber	rous Sclerosis Complex, ple	ase answe	r the follow	ving questions:			
Is the member on a ketogenic diet? Yes No If not, please provide rationale for why this might be inappropriate:							
as the memori on a netogethe diet 1 es 1 to 1 hot, please provide fationale for why this hight be mappropriate.							
If the member has a glioneuronal hamartoma or tuber, have they failed surgical management? Yes No							
If not, please provide rationale for why this might be inappropriate:							
CURRENT or PREVIOUS THERAPY							
Modication Nama	1						
Medication Name	Strength/ Frequency	Dates of	Therapy	Status (Discontinued & Why/Current)			



Updated: 10/2020 DMMA Approved: 10/2020

CANNABIDIOL (EPIDIOLEX) (PAGE 2 of 2) PRIOR AUTHORIZATION FORM

Please complete and fax all requested information below including any progress notes, laboratory test results, or chart documentation as applicable to Highmark Health Options Pharmacy Services. **FAX:** (855) 476-4158

If needed, you may call to speak to a Pharmacy Services Representative.

If needed, you may call to speak to a	a Pharmacy Services Represe	entative.					
PHONE : (844) 325-6251 Monday through Friday 8:30am to 5:00pm							
MEMBER INFORMATION							
Member Name:	DOB:						
Health Options ID:	Member weight:	pounds or	kg				
REAUTHORIZATION							
Has the member experienced a significant improvement with treatment? Yes No							
Please describe:							
SUPPORTING INFORMATION or CLINICAL RATIONALE							
Prescribing Provider Signature		Date					
-							